Plant Comparison
Astragalus vs Lingzhi
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Astragalus and Lingzhi: they share 7 indicated uses (arthritis / joint pain, cancer (anticancer research), cold & flu, …); 4 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Astragalus | Lingzhi | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Cancer (anticancer research) | 2/10 | 8/10 | Stronger for Lingzhi |
| Cold & flu | 2/10 | 1/10 | Comparable evidence |
| Immune support | 2/10 | 1/10 | Comparable evidence |
| Infection (general) | 2/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 1/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Major bioactive saponin with cardio-, neuro-, hepato- and renoprotective effects.
Principal immunomodulatory constituents, the main focus of anticancer-adjunct and immune research.
Bitter triterpenes associated with anti-inflammatory, hepatoprotective and adaptogenic activity.
Pharmacological Actions
Astragalus membranaceus and its constituents (astragaloside IV, cycloastragenol, Astragalus polysaccharide) inhibit tumour growth, invasion and metastasis and enhance antitumour immunity across lung, colorectal and gastrointestinal cancers (preclinical, incl. in vivo).
Immune support / immunomodulation (activates macrophages, NK cells, T and B lymphocytes)
Traditional & Indicated Uses
inferred from anti-inflammatory action
Astragalus membranaceus protects against gastrointestinal cancers; astragaloside IV inhibits lung cancer metastasis via macrophage repolarization, cycloastragenol boosts CD8+ T-cell antitumour immunity (with anti-PD-1 synergy), and Astragalus polysaccharide suppresses inflammation-induced colorectal cancer (preclinical).
Supports resistance to colds and respiratory infection (immune)
Adaptogenic tonic for fatigue and low vitality (traditional 'Qi' tonic)
Immune support / immunomodulation (activates macrophages, NK cells, T and B lymphocytes); Supports resistance to colds and respiratory infection (immune)
Supports resistance to colds and respiratory infection (immune)
inferred from anti-inflammatory action
Renoprotective (kidney support) - as an adjunct in chronic kidney disease, reduced proteinuria and raised haemoglobin and serum albumin across trials (Cochrane review; study quality low)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from antidiabetic action
inferred from anticancer action
inferred from antiviral action
inferred from anti-inflammatory action
inferred from sedative action
inferred from antidiabetic action
Safety, Cautions & Contraindications
Astragalus stimulates immune activity; on theoretical grounds it should be used cautiously in autoimmune disease and with immunosuppressant medicines (for example after organ transplant) - discuss with a clinician.
Generally well tolerated; high-quality long-term human safety and toxicity data remain limited.
Safety in pregnancy and breastfeeding has not been established; avoid medicinal doses.
Generally well tolerated at standard doses. May cause mild digestive upset, dry mouth, or dizziness in some individuals. May enhance the effects of anticoagulant and antihypertensive medications. Avoid during pregnancy and breastfeeding. Extended use beyond 6 months is not well studied in humans.
Duke (2002) rates reishi (Ganoderma lucidum) as + and notes immunostimulant, hepatoprotective, antioxidant, antitumor, and hypoglycemic activities at the experimental level (score 1). It is a key adaptogen in traditional Chinese medicine, valued for its polysaccharide (beta-glucan) content. Duke notes antiviral (score 1) and anti-aggregant activities. No strong clinical trials existed at time of publication, but lentinan and polysaccharide fractions from related species show immunomodulatory potential. Duke suggests caution in bleeding disorders due to anti-aggregant activity (Duke, 2002).
External Ids
Botanical Description
Erect perennial herb with a long, fibrous, pale yellow taproot. The leaves are pinnately compound with numerous small, oval leaflets, giving a soft, ferny appearance. Small, pale yellow, pea-like flowers are borne in loose axillary clusters (racemes), followed by membranous, inflated seed pods that give the species its name.[5]
Bracket (shelf) fungus (not a true plant) that grows on the trunks and stumps of deciduous trees. It develops a hard, kidney- or fan-shaped cap with a glossy, varnished, red-brown to mahogany crust and concentric growth rings, often on a lateral woody stalk; the pale underside is covered in fine pores that release rusty-brown spores. The mycelium spreads through the wood substrate before fruiting.[1]
Habitat
Native to the grasslands, sunny slopes and forest margins of northern and north-eastern China, Mongolia and parts of Korea; widely cultivated as a medicinal crop across East Asia.[5]
Grows as a wood-decay fungus on the stumps and trunks of deciduous trees (notably maple and other hardwoods) in East Asian forests; also widely cultivated commercially on hardwood logs or sawdust substrate.
Harvesting
The root is dug from plants at least four years old, typically in spring or autumn, then cleaned and dried, often sliced into the characteristic pale, fibrous 'coin' slices used in traditional decoctions.[5]
Wild fruiting bodies are collected once mature; cultivated material is harvested from logs or substrate at maturity, then dried and processed into slices, powder or extract.
Traditional Uses
Reishi/lingzhi, the 'mushroom of immortality', is one of the most revered tonic fungi in traditional Chinese medicine, used for centuries to support vitality, calm the spirit, strengthen immunity and promote longevity; this traditional tonic reputation is now studied for immunomodulatory, anticancer-adjunct and metabolic effects.[1, 4]
Preparations
Dosage
The WHO monograph on Radix Astragali gives doses of 3-9 g per day. Traditional Chinese medicine references often cite a considerably higher 9-30 g of dried root per day; WHO's figure is the conservative regulatory-tier one and is stated here in preference. Educational reference only, not a prescription.
Clinical studies commonly use extracts providing the equivalent of several grams of dried root daily, in divided doses. Educational reference only, not a prescription.
Not documented
References
Lookalikes Review
Drug Class Interactions
Not documented
Dangerous Lookalikes
Not documented
References & Sources
- Xu, B., Huang, J.P., Peng, G., Cao, W., Liu, Z. et al (2024) 'Total biosynthesis of the medicinal triterpenoid saponin astragalosides', Nature Plants, 10(11), pp. 1826-1837. doi:10.1038/s41477-024-01827-4 Preclinical
https://doi.org/10.1038/s41477-024-01827-4 - Auyeung, K.K., Han, Q.B. and Ko, J.K (2016) 'Astragalus membranaceus: A Review of its Protection Against Inflammation and Gastrointestinal Cancers', The American Journal of Chinese Medicine, 44(1), pp. 1-22. doi:10.1142/S0192415X16500014 Traditional / reference
https://doi.org/10.1142/S0192415X16500014 - Zhang, Y., Ji, W., Qin, H., Chen, Z., Zhou, Y. et al (2024) 'Astragalus polysaccharides alleviate DSS-induced ulcerative colitis in mice by restoring SCFA production and regulating Th17/Treg cell homeostasis in a microbiota-dependent manner', Carbohydrate Polymers, 349, pp. 122829. doi:10.1016/j.carbpol.2024.122829 Preclinical
https://doi.org/10.1016/j.carbpol.2024.122829 - Fu, J., Wang, Z., Huang, L., Zheng, S., Wang, D., Chen, S., Zhang, H. and Yang, S (2014) 'Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi)', Phytotherapy Research, 28(9), pp. 1275-1283. doi:10.1002/ptr.5188 Meta-analysis / review
https://doi.org/10.1002/ptr.5188 - Zhang, J., Wu, C., Gao, L., Du, G. and Qin, X (2019) 'Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects', Advances in Pharmacology. doi:10.1016/bs.apha.2019.08.002 Traditional / reference
https://doi.org/10.1016/bs.apha.2019.08.002 - Dong, M., Li, J., Yang, D., Li, M. and Wei, J (2023) 'Biosynthesis and pharmacological activities of flavonoids, triterpene saponins and polysaccharides derived from Astragalus membranaceus', Molecules, 28(13), pp. 5018. doi:10.3390/molecules28135018 Meta-analysis / review
https://doi.org/10.3390/molecules28135018 - Chen, G., Jiang, N., Zheng, J., Hu, H., Yang, H., Lin, A., Hu, B. and Liu, H (2023) 'Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus', International Journal of Biological Macromolecules, 241, pp. 124386. doi:10.1016/j.ijbiomac.2023.124386 Preclinical
https://doi.org/10.1016/j.ijbiomac.2023.124386 - Zheng, Q., Zhuang, Z., Wang, Z., Deng, L., Jin, W., Huang, Z., Zheng, G. and Wang, Y (2020) 'Clinical and preclinical systematic review of Astragalus membranaceus for viral myocarditis', Oxidative Medicine and Cellular Longevity, 2020, pp. 1560353. doi:10.1155/2020/1560353 Meta-analysis / review
https://doi.org/10.1155/2020/1560353 - Dai, Y., Wang, Y., Kang, Q., Wu, Y., Liu, Y., Su, Y., Wang, X., Xiu, M. and He, J (2024) 'The protective effect and bioactive compounds of Astragalus membranaceus against neurodegenerative disorders via alleviating oxidative stress in Drosophila', FASEB Journal, 38(13), pp. e23727. doi:10.1096/fj.202400390R Preclinical
https://doi.org/10.1096/fj.202400390R - Xu, L., Xu, X., Hou, X., Wang, F., Gao, S. and Zhang, H (2019) 'Adjuvant therapy with Astragalus membranaceus for post-stroke fatigue: a systematic review', Metabolic Brain Disease, 35(1), pp. 83-93. doi:10.1007/s11011-019-00483-4 Meta-analysis / review
https://doi.org/10.1007/s11011-019-00483-4 - Li, C.X., Liu, Y., Zhang, Y.Z., Li, J.C. and Lai, J (2022) 'Astragalus polysaccharide: a review of its immunomodulatory effect', Archives of Pharmacal Research. doi:10.1007/s12272-022-01393-3 Preclinical
https://doi.org/10.1007/s12272-022-01393-3 - Jin, M., Zhao, K., Huang, Q. and Shang, P (2014) 'Structural features and biological activities of the polysaccharides from Astragalus membranaceus', International Journal of Biological Macromolecules, 64, pp. 257-266. doi:10.1016/j.ijbiomac.2013.12.002 Preclinical
https://doi.org/10.1016/j.ijbiomac.2013.12.002 - Liu, Y. and Lv, W (2019) 'Research progress in Astragalus membranaceus and its active components on immune responses in liver fibrosis', Chinese Journal of Integrative Medicine, 26(10), pp. 794-800. doi:10.1007/s11655-019-3039-1 Meta-analysis / review
https://doi.org/10.1007/s11655-019-3039-1 - World Health Organization (1999) 'Radix Astragali'. Available at: https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 Traditional / reference
https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 - Xu, F. and Cui, W.-Q. and Wei, Y. and Cui, J. and Qiu, J. and Hu, L.-L. and Gong, W.-Y. and Dong, J.-C. and Liu, B.-J (2018) 'Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling', Journal of Experimental & Clinical Cancer Research, 37(1), pp. 207. doi:10.1186/s13046-018-0878-0 Preclinical
https://doi.org/10.1186/s13046-018-0878-0 - Deng, G. and Zhou, L. and Wang, B. and Sun, X. and Zhang, Q. and Chen, H. and Wan, N. and Ye, H. and Wu, X. and Sun, D. and Sun, Y. and Cheng, H (2022) 'Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation', Journal for ImmunoTherapy of Cancer, 10(10), pp. e004874. doi:10.1136/jitc-2022-004874 Preclinical
https://doi.org/10.1136/jitc-2022-004874 - Li, Q. and Zhang, C. and Xu, G. and Shang, X. and Nan, X. and Li, Y. and Liu, J. and Hong, Y. and Wang, Q. and Peng, G (2024) 'Astragalus polysaccharide ameliorates CD8 T cell dysfunction through STAT3/Gal-3/LAG3 pathway in inflammation-induced colorectal cancer', Biomedicine & Pharmacotherapy, 171, pp. 116172. doi:10.1016/j.biopha.2024.116172 Preclinical
https://doi.org/10.1016/j.biopha.2024.116172 - Zhang, H.W., Lin, Z.X., Xu, C., Leung, C. and Chan, L.S (2014) 'Astragalus (a traditional Chinese medicine) for treating chronic kidney disease', Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD008369.pub2 Meta-analysis / review
https://doi.org/10.1002/14651858.CD008369.pub2
- Li, W., Zhou, Q., Lv, B., Li, N. et al (2024) 'Ganoderma lucidum Polysaccharide Supplementation Significantly Activates T-Cell-Mediated Antitumor Immunity and Enhances Anti-PD-1 Immunotherapy Efficacy in Colorectal Cancer', Journal of Agricultural and Food Chemistry, 72(21), pp. 12072-12082. doi:10.1021/acs.jafc.3c08385 Preclinical
https://doi.org/10.1021/acs.jafc.3c08385 - Cai, Q., Li, Y. and Pei, G (2017) 'Polysaccharides from Ganoderma lucidum attenuate microglia-mediated neuroinflammation and modulate microglial phagocytosis and behavioural response', Journal of Neuroinflammation, 14(1), pp. 63. doi:10.1186/s12974-017-0839-0 Preclinical
https://doi.org/10.1186/s12974-017-0839-0 - Zheng, G., Zhao, Y., Li, Z., Hua, Y. et al (2023) 'Ganoderma lucidum spore powder and derived triterpenes attenuate atherosclerosis and aortic calcification by stimulating ABCA1/G1-mediated macrophage cholesterol efflux and inactivating RUNX2-mediated VSMC osteogenesis', Theranostics, 13(4), pp. 1325-1341. doi:10.7150/thno.80250 Preclinical
https://doi.org/10.7150/thno.80250 - Sohretoglu, D. and Huang, S (2018) 'Ganoderma lucidum Polysaccharides as An Anti-cancer Agent', Anti-Cancer Agents in Medicinal Chemistry, 18(5), pp. 667-674. doi:10.2174/1871520617666171113121246 Meta-analysis / review
https://doi.org/10.2174/1871520617666171113121246 - Seweryn, E., Ziala, A. and Gamian, A (2021) 'Health-Promoting of Polysaccharides Extracted from Ganoderma lucidum', Nutrients, 13(8), pp. 2725. doi:10.3390/nu13082725 Meta-analysis / review
https://doi.org/10.3390/nu13082725 - Liu, X., Yang, L., Li, G., Jiang, Y., Zhang, G. and Ling, J (2022) 'A novel promising neuroprotective agent: Ganoderma lucidum polysaccharide', International Journal of Biological Macromolecules, 229, pp. 168-180. doi:10.1016/j.ijbiomac.2022.12.276 Meta-analysis / review
https://doi.org/10.1016/j.ijbiomac.2022.12.276 - Zhu, M., Chang, Q., Wong, L.K., Chong, F.S. and Li, R.C (1999) 'Triterpene antioxidants from Ganoderma lucidum', Phytotherapy Research, 13(6), pp. 529-531. doi:10.1002/(sici)1099-1573(199909)13:6<529::aid-ptr481>3.0.co;2-x Preclinical
https://doi.org/10.1002/(sici)1099-1573(199909)13:6<529::aid-ptr481>3.0.co;2-x - Zeng, P., Chen, Y., Zhang, L. and Xing, M (2019) 'Ganoderma lucidum polysaccharide used for treating physical frailty in China', Progress in Molecular Biology and Translational Science, 163, pp. 179-219. doi:10.1016/bs.pmbts.2019.02.009 Meta-analysis / review
https://doi.org/10.1016/bs.pmbts.2019.02.009 - Wu, P., Zhang, C., Yin, Y., Zhang, X., Li, Q., Yuan, L., Sun, Y., Zhou, S., Ying, S. and Wu, J (2024) 'Bioactivities and industrial standardization status of Ganoderma lucidum: A comprehensive review', Heliyon, 10(19), pp. e36987. doi:10.1016/j.heliyon.2024.e36987 Meta-analysis / review
https://doi.org/10.1016/j.heliyon.2024.e36987 - Xu, Z., Chen, X., Zhong, Z., Chen, L. and Wang, Y (2011) 'Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities', The American Journal of Chinese Medicine, 39(1), pp. 15-27. doi:10.1142/S0192415X11008610 Meta-analysis / review
https://doi.org/10.1142/S0192415X11008610 - Geng, X., Zhong, D., Su, L., Lin, Z. and Yang, B (2019) 'Preventive and therapeutic effect of Ganoderma lucidum on kidney injuries and diseases', Advances in Pharmacology, 87, pp. 257-276. doi:10.1016/bs.apha.2019.10.003 Meta-analysis / review
https://doi.org/10.1016/bs.apha.2019.10.003 - Sliva, D (2004) 'Cellular and physiological effects of Ganoderma lucidum (Reishi)', Mini Reviews in Medicinal Chemistry, 4(8), pp. 873-879. doi:10.2174/1389557043403323 Meta-analysis / review
https://doi.org/10.2174/1389557043403323 - Boh, B., Berovic, M., Zhang, J. and Zhi-Bin, L (2007) 'Ganoderma lucidum and its pharmaceutically active compounds', Biotechnology Annual Review, 13, pp. 265-301. doi:10.1016/S1387-2656(07)13010-6 Meta-analysis / review
https://doi.org/10.1016/S1387-2656(07)13010-6 - Bao, X. et al (2001) 'Structural requirements for the immunological activities of polysaccharides from Ganoderma lucidum', 41(9), pp. 2603--2611. Traditional / reference
https://scholar.google.com/scholar?q=Structural%20requirements%20for%20the%20immunological%20activities%20of%20polysaccharides%20from%20Ganoderma%20lucidum - Jin, X. et al (2012) 'Ganoderma lucidum (Reishi mushroom) for cancer treatment'. Traditional / reference
https://scholar.google.com/scholar?q=Ganoderma%20lucidum%20%28Reishi%20mushroom%29%20for%20cancer%20treatment - Wachtel-Galor, S., Yuen, J., Buswell, J.A. and Benzie, I.F.F (2011) 'Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom'. Traditional / reference
https://scholar.google.com/scholar?q=Ganoderma%20lucidum%20%28Lingzhi%20or%20Reishi%29%3A%20A%20Medicinal%20Mushroom - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
https://doi.org/10.1002/ptr.8201 - Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
https://doi.org/10.1177/1534735404265003 - Ahn, J.Y. and Seok, S.J. and Song, J.E. and Choi, J.H. and Han, S.H. and Choi, J.Y. and Kim, C.O. and Song, Y.G. and Kim, J.M (2013) 'Two cases of mushroom poisoning by Podostroma cornu-damae', Yonsei Medical Journal, 54(1), pp. 265-8. doi:10.3349/ymj.2013.54.1.265 Clinical study
https://doi.org/10.3349/ymj.2013.54.1.265 - Choe, S. and In, S. and Jeon, Y. and Choi, H. and Kim, S (2018) 'Identification of trichothecene-type mycotoxins in toxic mushroom Podostroma cornu-damae and biological specimens from a fatal case by LC-QTOF/MS', Forensic Science International, 291, pp. 234-244. doi:10.1016/j.forsciint.2018.08.043 Clinical study
https://doi.org/10.1016/j.forsciint.2018.08.043
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.